PFE

EX-99

2 pfe-3292026xex99.htm

EX-99

Document

Exhibit 99

g

Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance

■Earnings Driven by Focused Execution and 22% Op Revenue Growth of Launched and Acquired Products(1)

■Pipeline Momentum Builds on Positive Phase 3 and Mid-Stage Readouts

■Robust Late‑Stage R&D Pipeline, On Track to Start ~20 Key Pivotal Studies in 2026

NEW YORK, Tuesday, May 5, 2026 — Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2026 and reaffirmed its full-year 2026 financial guidance(2).

EXECUTIVE COMMENTARY

Dr. Albert Bourla, Chairman and CEO of Pfizer:

“We're off to a strong start in 2026, and it reinforces our confidence that we will successfully navigate this defining period for Pfizer. Our R&D pipeline is advancing on multiple fronts – with positive Phase 3 readouts and encouraging mid-stage results building meaningful momentum – and I'm particularly encouraged by what we're seeing in oncology and obesity, two areas where I believe Pfizer is positioned to lead.”

David Denton, CFO and EVP of Pfizer:

“Our first-quarter results are attributable to our solid commercial performance globally as well as our ongoing focus on operational efficiency. This quarter, I’m particularly pleased with the 22% year-over-year operational revenue growth from our launched and acquired products(1). Today, we are reaffirming our full-year 2026 financial guidance.”

OVERALL RESULTS

■First-Quarter 2026 Revenues of $14.5 Billion, Representing 2% Year-over-Year Operational Growth

–Excluding Contributions from Comirnaty and Paxlovid, Revenues Grew 7% Operationally

–Revenues of Launched and Acquired Products(1) Grew 22% Operationally

■First-Quarter 2026 Reported(3) Diluted EPS of $0.47, and Adjusted(4) Diluted EPS of $0.75

■Reaffirms All Components of Full-Year 2026 Financial Guidance(2), including Revenues in a Range of $59.5 to $62.5 Billion and Adjusted(4) Diluted EPS in a Range of $2.80 to $3.00

- 1 -

Beginning in the first quarter of 2026, we made organizational changes in our commercial organization within the Global Biopharmaceuticals Business (Biopharma) to better support and optimize performance across our product portfolios. These changes include the transition of certain off-patent branded and generic sterile injectables and biosimilars primarily from the Specialty Care and Oncology product portfolios to a new Hospital and Biosimilars product portfolio and the creation of a new Global Hospital and Biosimilars Division within Biopharma. See the Item 1. Business––Commercial Operations section of Pfizer's 2025 Annual Report on Form 10-K (available at www.pfizer.com and www.sec.gov).

Some amounts in this press release may not add due to rounding. All percentages have been calculated using unrounded amounts. References to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates(5).

Results for the first quarter of 2026 and 2025(6) are summarized below.

($ in millions, except per share amounts) First-Quarter

20262025 % Change

Revenues$ 14,451 $ 13,715 5%

Reported(3) Net Income 2,687 2,967 (9%)

Reported(3) Diluted EPS 0.47 0.52 (10%)

Adjusted(4) Income 4,290 5,237 (18%)

Adjusted(4) Diluted EPS 0.75 0.92 (18%)

REVENUES

($ in millions)First-Quarter

20262025% Change

TotalOper.

Global Biopharmaceuticals Business (Biopharma)$ 14,161 $ 13,441 5%2%

Pfizer CentreOne 289 273 6%1%

TOTAL REVENUES$ 14,451 $ 13,715 5%2%

- 2 -

2026 FINANCIAL GUIDANCE(2)

■Reaffirms all components of full-year 2026 Financial Guidance(2), including Revenues in a range of $59.5 to $62.5 billion and Adjusted(4) Diluted EPS in a Range of $2.80 to $3.00.

Revenues $59.5 to $62.5 billion

Adjusted(4) SI&A Expenses

$12.5 to $13.5 billion

Adjusted(4) R&D Expenses

$10.5 to $11.5 billion

Effective Tax Rate on Adjusted(4) Income

Approximately 15.0%

Adjusted(4) Diluted EPS

$2.80 to $3.00

CAPITAL ALLOCATION

During the first three months of 2026, Pfizer deployed its capital in a variety of ways, which primarily included:

▪Reinvesting capital into initiatives intended to enhance the future growth prospects of the company, including:

•$2.5 billion invested in internal research and development projects, and

•Approximately $110 million invested in business development transactions.

▪Returning capital directly to shareholders through $2.4 billion of cash dividends, or $0.43 per share of common stock.

Our capital allocation framework is designed to enhance long-term shareholder value, and is based on three core pillars: (i) reinvesting in the business, including maintaining the flexibility to deploy capital towards potential value-creating business development transactions, (ii) maintaining and, over the long term, growing our dividend, and (iii) in the future, the potential to resume the return of capital to shareholders through value-enhancing share repurchases after de-levering our balance sheet. The company expe

pfe-202602030000078003false00000780032026-02-032026-02-030000078003us-gaap:CommonStockMember2026-02-032026-02-030000078003pfe:NotesDue20271.000Member2026-02-032026-02-030000078003pfe:NotesDue20292.875Member2026-02-032026-02-030000078003pfe:NotesDue20323.250Member2026-02-032026-02-030000078003pfe:NotesDue20373.875Member2026-02-032026-02-030000078003pfe:NotesDue20454.250Member2026-02-032026-02-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 3, 2026

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)

66 Hudson Boulevard East10001-2192 New York, New York (Zip Code)

(Address of principal executive offices)

Registrant’s telephone number, including area code: (212) 733-2323

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE/27 New York Stock Exchange 2.875% Notes due 2029

PFE/29

New York Stock Exchange 3.250% Notes due 2032

PFE/32

New York Stock Exchange 3.875% Notes due 2037

PFE/37A

New York Stock Exchange 4.250% Notes due 2045

PFE/45

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company    ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐

Item 2.02 Results of Operations and Financial Condition

On February 3, 2026, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the fourth quarter of 2025. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.

The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits (d)  Exhibits

Exhibit NumberExhibit Description

Exhibit 99 Press Release of Pfizer Inc. dated February 3, 2026, reporting Pfizer’s financial results for the fourth quarter of 2025.

104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

EXHIBIT INDEX

Exhibit No.Description

99 Press Release of Pfizer Inc. dated February 3, 2026, reporting Pfizer’s financial results for the fourth quarter of 2025.

104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PFIZER INC.

By:/s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel

Dated: February 3, 2026

pfe-202511040000078003false00000780032025-11-042025-11-040000078003us-gaap:CommonStockMember2025-11-042025-11-040000078003pfe:NotesDue20271.000Member2025-11-042025-11-040000078003pfe:NotesDue20292.875Member2025-11-042025-11-040000078003pfe:NotesDue20323.250Member2025-11-042025-11-040000078003pfe:NotesDue20373.875Member2025-11-042025-11-040000078003pfe:NotesDue20454.250Member2025-11-042025-11-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 4, 2025

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)

66 Hudson Boulevard East10001-2192 New York, New York (Zip Code)

(Address of principal executive offices)

Registrant’s telephone number, including area code: (212) 733-2323

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE/27 New York Stock Exchange 2.875% Notes due 2029

PFE/29

New York Stock Exchange 3.250% Notes due 2032

PFE/32

New York Stock Exchange 3.875% Notes due 2037

PFE/37A

New York Stock Exchange 4.250% Notes due 2045

PFE/45

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company    ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐

Item 2.02 Results of Operations and Financial Condition

On November 4, 2025, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the third quarter of 2025. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.

The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits (d)  Exhibits

Exhibit NumberExhibit Description

Exhibit 99 Press Release of Pfizer Inc. dated November 4, 2025, reporting Pfizer’s financial results for the third quarter of 2025.

104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

EXHIBIT INDEX

Exhibit No.Description

99 Press Release of Pfizer Inc. dated November 4, 2025, reporting Pfizer’s financial results for the third quarter of 2025.

104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PFIZER INC.

By:/s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel

Dated: November 4, 2025